Annals of Surgical Oncology

, Volume 17, Issue 4, pp 1152–1158

Influence of Sentinel Lymph Node Tumor Burden on Survival in Melanoma

  • Thiago Francischetto
  • Nelson Spector
  • Jose Francisco Neto Rezende
  • Marcelle de Azevedo Antunes
  • Sergio de Oliveira Romano
  • Isabele A. Small
  • Carlos Gil Ferreira
Melanomas

Abstract

Background

Completion lymph node dissection (CLND) is the standard procedure for patients with positive sentinel lymph nodes (SLN). With extensive pathological workup, increased numbers of small metastatic deposits are detected in SLN. This study evaluated the prognostic significance of SLN metastatic deposits ≤ 0.2 mm in patients treated in a referral cancer center in Brazil.

Methods

Patients with stage I/II melanoma, consecutively submitted to a SLN procedure by the same surgeon from 2000 to 2006, were evaluated. All positive SLN and randomly selected negative cases were reviewed by two pathologists. Different prognostic factors and SLN tumor burden were recorded. Additional positive non-SLN after CLND, and disease outcome were evaluated.

Results

Of 381 patients who underwent SLN biopsy, 103 (27%) were positive. The mean/median Breslow tumor thickness in the overall group was 3.4/2.0 mm and in the SLN positive patients was 5.72/4.0 mm. Among these patients, 48 (47%) had metastatic deposits >2 mm (macrometastasis), 49 (47%) had metastatic deposits ≤2 mm but >0.2 mm (micrometastasis), and 6 (6%) had metastatic deposits ≤0.2 mm (submicrometastasis). Additional positive non-SLN were detected in 29% of patients with macrometastasis, in 25% of patients with micrometastasis, and in 0% of patients with submicrometastases. At median follow-up of 35 months, the estimated 3-year overall survival was 92% for negative SLN, 64% for micrometastases, 53% for macrometastases, and 100% for submicrometastases (P < 0.001).

Conclusion

In the present study, patients with SLN metastatic deposits ≤0.2 mm had no additional positive non-SLNs, and no recurrences or deaths were recorded, suggesting that their prognosis is equivalent to that of patients with negative SLN.

References

  1. 1.
    Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.PubMedGoogle Scholar
  2. 2.
    Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–34.PubMedGoogle Scholar
  3. 3.
    Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma. A multicenter trial. Ann Surg. 1999;230:453–65.CrossRefPubMedGoogle Scholar
  4. 4.
    Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg. 1994;6:759–67.CrossRefGoogle Scholar
  5. 5.
    Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging for cutaneous melanoma. Cancer. 2000;88:1484–91.CrossRefPubMedGoogle Scholar
  6. 6.
    Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.CrossRefPubMedGoogle Scholar
  7. 7.
    McMasters KM, Wong SL, Edwards MJ, et al. Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol. 2002;9:137–41.CrossRefPubMedGoogle Scholar
  8. 8.
    van der Ploeg IMC, Kroon BBR, Antonini N, et al. Comparison of three micromorphometric pathology classifications of melanoma metastases in the sentinel node. Ann Surg. 2009;250:301–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Hermanek P, Hutter RVP, Sobin LH, Wittekind C. Classification of isolated tumor cells and micrometastasis. Cancer. 1999;86:2668–73.CrossRefPubMedGoogle Scholar
  10. 10.
    Gibbs JF, Huang PP, Zhang PJ, et al. Accuracy of pathologic techniques for the diagnosis of metastatic melanoma in sentinel lymph nodes. Ann Surg Oncol. 1999;6:699–704.PubMedGoogle Scholar
  11. 11.
    Yu LL, Flotte TJ, Tanabe KK, et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer. 1999;86:616–27.CrossRefGoogle Scholar
  12. 12.
    Abrahamsen HN, Hamilton-Dutoit SJ, Jørn Larsen J, Steiniche T. Sentinel lymph nodes in malignant melanoma. Extended histopathologic evaluation improves diagnostic precision. Cancer. 2004;100:1683–91.CrossRefPubMedGoogle Scholar
  13. 13.
    Spanknebel K, Coit DG, Bieligk SM, et al. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol. 2005;29:305–17.CrossRefPubMedGoogle Scholar
  14. 14.
    Starz H, Balda BR, Kramer KU, et al. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer. 2001;91:2110–20.CrossRefPubMedGoogle Scholar
  15. 15.
    van Akkooi ACJ, de Wilt JHW, Verhoef C, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol. 2006;17:1578–85.CrossRefPubMedGoogle Scholar
  16. 16.
    Dewar DJ, Newell B, Green MA, et al. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol. 2004;22:3345–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Greene FL, Page DL, Balch CM, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 6th ed. New York: Springer-Verlag; 2002.Google Scholar
  18. 18.
    Govindarajan A, Ghazarian DM, McCready DR, Leong WL. Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse. Ann Surg Oncol. 2007;14:906–12.CrossRefPubMedGoogle Scholar
  19. 19.
    Sheri RP, Essner R, Turner RR, et al. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol. 2007;14(10):2861–66.Google Scholar
  20. 20.
    van Akkooi ACJ, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients. Ann Surg. 2008;248:949–55.CrossRefPubMedGoogle Scholar
  21. 21.
    Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol. 2006;17(1):5–19.CrossRefPubMedGoogle Scholar
  22. 22.
    Carlson GW, Murray DR, Lyles RH, et al. The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol. 2003;10:575–81.CrossRefPubMedGoogle Scholar
  23. 23.
    Lee JH, Essner R, Morton DL, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004;22:3677–84.CrossRefPubMedGoogle Scholar
  24. 24.
    Reeves ME, Delgado R, Busam KJ, et al. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol. 2003;10:27–31.CrossRefPubMedGoogle Scholar
  25. 25.
    Satzger I, Volker B, Ghazal MA, et al. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. Histopathology. 2007;50:764–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Guggenheim M, Dummer R, Jung FJ, et al. The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma—a retrospective analysis of 392 cases. Br J Cancer. 2008;98:1922–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Ranieri JM, Wagner JD, Azuaje R, et al. Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy. Ann Surg Oncol. 2002;9(10):975–81.CrossRefPubMedGoogle Scholar
  28. 28.
    Wagner JD, Davidson D, Coleman JJ, et al. Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma. Ann Surg Oncol. 1999;6:398–404.CrossRefPubMedGoogle Scholar
  29. 29.
    Cochran AJ, Wen DR, Huang RR, et al. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on primary melanoma and the sentinel node. Mod Pathol. 2004;17:747–55.CrossRefPubMedGoogle Scholar
  30. 30.
    Vuylsteke RJCLM, Borstein PJ, van Leeuwen PAM, et al. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma. Ann Surg Oncol. 2006;12:1–9.Google Scholar

Copyright information

© Society of Surgical Oncology 2010

Authors and Affiliations

  • Thiago Francischetto
    • 1
    • 6
  • Nelson Spector
    • 2
  • Jose Francisco Neto Rezende
    • 3
  • Marcelle de Azevedo Antunes
    • 4
  • Sergio de Oliveira Romano
    • 4
  • Isabele A. Small
    • 5
  • Carlos Gil Ferreira
    • 5
  1. 1.Division of Surgical OncologyInstituto Nacional de CâncerRio de JaneiroBrazil
  2. 2.Department of Medicine, Hematology Service, School of MedicineFederal University of Rio de JaneiroRio de JaneiroBrazil
  3. 3.Department of Bone Connective TissueInstituto Nacional de CâncerRio de JaneiroBrazil
  4. 4.Department of PathologyInstituto Nacional de CâncerRio de JaneiroBrazil
  5. 5.Division of Clinical and Translational ResearchInstituto Nacional de CâncerRio de JaneiroBrazil
  6. 6.SalvadorBrazil

Personalised recommendations